CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

Tom Schalekamp; Gerard J. J. Boink; Loes E. Visser; Bruno H. Ch Stricker; Anthonius de Boer; Olaf H. Klungel

doi:https://doi.org/10.1016/j.clpt.2006.03.008

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

Tom Schalekamp, Gerard J. J. Boink, Loes E. Visser, Bruno H. Ch Stricker, Anthonius de Boer, Olaf H. Klungel

Cardiology (AMC)

Research output: Contribution to journal › Editorial › Academic › peer-review

36 Citations (Scopus)

Original language	English
Pages (from-to)	511-520
Journal	Clinical Pharmacology and Therapeutics
Volume	79
Issue number	6
DOIs	https://doi.org/10.1016/j.clpt.2006.03.008
Publication status	Published - 2006

Access to Document

https://doi.org/10.1016/j.clpt.2006.03.008

Cite this

@article{bf271d94af45417b9fce2cc4537c805a,

title = "CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?",

author = "Tom Schalekamp and Boink, {Gerard J. J.} and Visser, {Loes E.} and Stricker, {Bruno H. Ch} and {de Boer}, Anthonius and Klungel, {Olaf H.}",

year = "2006",

doi = "https://doi.org/10.1016/j.clpt.2006.03.008",

language = "English",

volume = "79",

pages = "511--520",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",